Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

Decitabine Synergizes with Replication Checkpoint Inhibitors in TP53 -Mutated Acute Myeloid Leukemia

Clifford M. Csizmar, Antoine N. Saliba, Kevin L. Peterson, Xue Wei Meng, B. Douglas Smith, Gabriel Ghiaur, Mrinal M. Patnaik, Scott H. Kaufmann

Blood (2024) 144 (Supplement 1): 5782.

https://doi.org/10.1182/blood-2024-208583

Published: 2024

Journal Articles

Topoisomerase I-DNA Covalent Complexes in Myeloid Malignancies: A Potential Biomarker for Topoisomerase I Inhibitor Sensitivity

Mira A. Kohorst, MD, Karen S. Flatten, Kevin L. Peterson, Paula A. Schneider, Cristina Correia, Keith W. Pratz, MD, B. Douglas Smith, MD, Scott H. Kaufmann, MD PhD

Blood (2018) 132 (Supplement 1): 5146.

https://doi.org/10.1182/blood-2018-99-115667

Published: 2018

Journal Articles

4EBP1/c-MYC/PUMA and NF-κB/EGR1/BIM pathways underlie cytotoxicity of mTOR dual inhibitors in malignant lymphoid cells

Seongseok Yun, Nicole D. Vincelette, Katherine L. B. Knorr, Luciana L. Almada, Paula A. Schneider, Kevin L. Peterson, Karen S. Flatten, Haiming Dai, Keith W. Pratz, Allan D. Hess, B. Douglas Smith, Judith E. Karp, Andrea E. Wahner Hendrickson, Martin E. Fernandez-Zapico, Scott H. Kaufmann

Blood (2016) 127 (22): 2711–2722.

https://doi.org/10.1182/blood-2015-02-629485

Published: 2016

Includes: Supplemental data

Journal Articles

mTOR Dual Inhibitor Induced Cytotoxicity Depends on 4EBP1/c-Myc/Puma and NFkB/Egr-1/Bim Pathways in Human Lymphoid Malignancies

Seongseok Yun, MD PhD, Nicole D. Vincelette, Katherine L. B. Knorr, PhD, Luciana L. Almada, PhD, Paula A. Schneider, Kevin L. Peterson, PhD, Karen S. Flatten, Allan D. Hess, PhD, B. Douglas Smith, MD, Judith E. Karp, MD, Martin E. Fernandez-Zapico, MD, Scott H. Kaufmann, MD PhD

Blood (2015) 126 (23): 3705.

https://doi.org/10.1182/blood.V126.23.3705.3705

Published: 2015

Journal Articles

Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies

Mamta Gupta, Andrea E. Wahner Hendrickson, Seong Seok Yun, Jing Jing Han, Paula A. Schneider, Brian D. Koh, Mary J. Stenson, Linda E. Wellik, Jennifer C. Shing, Kevin L. Peterson, Karen S. Flatten, Allan D. Hess, B. Douglas Smith, Judith E. Karp, Sharon Barr, Thomas E. Witzig, Scott H. Kaufmann

Blood (2012) 119 (2): 476–487.

https://doi.org/10.1182/blood-2011-04-346601

Published: 2012

Includes: Supplemental data

Journal Articles

Cytotoxicity of farnesyltransferase inhibitors in lymphoid cells mediated by MAPK pathway inhibition and Bim up-regulation

Husheng Ding, Jennifer Hackbarth, Paula A. Schneider, Kevin L. Peterson, X. Wei Meng, Haiming Dai, Thomas E. Witzig, Scott H. Kaufmann

Blood (2011) 118 (18): 4872–4881.

https://doi.org/10.1182/blood-2011-02-334870

Published: 2011

Includes: Supplemental data

Journal Articles

OSI-027, a Dual TORC1/TORC2 Inhibitor, Induces Bim- and Puma-Mediated Apoptosis In Lymphoid Malignancy

Andrea E. Wahner Hendrickson, MD, Mamta Gupta, Ph.D, Seongseok Yun, Jennifer C. Shing, Paula A. Schneider, Kevin L. Peterson, Judith E. Karp, MD, Sharon Barr, Thomas E. Witzig, MD, Scott H. Kaufmann, MD, PhD

Blood (2010) 116 (21): 970.

https://doi.org/10.1182/blood.V116.21.970.970

Published: 2010

Journal Articles

A Phase II Study of the Farnesyltransferase Inhibitor Tipifarnib Demonstrates Anti-Tumor Activity In Patients with Relapsed and Refractory Lymphomas

Blood (2010) 116 (21): 287.

https://doi.org/10.1182/blood.V116.21.287.287

Published: 2010

Journal Articles

Long-Term Survival Analysis of the North American Intergroup Study C9011 Comparing Fludarabine (F) and Chlorambucil (C) in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL).

Kanti R. Rai, MD, Bercedis L. Peterson, Ph.D, Frederick R. Appelbaum, MD, Martin S. Tallman, MD, Andrew Belch, MD, Vicki A. Morrison, MD, Richard A. Larson, MD

Blood (2009) 114 (22): 536.

https://doi.org/10.1182/blood.V114.22.536.536

Published: 2009

Journal Articles

Consolidation Therapy with Subcutaneous (SC) Alemtuzumab Results in Severe Infectious Toxicity in Previously Untreated CLL Patients Who Achieve a Complete Response (CR) after Fludarabine and Rituximab (FR) Induction Therapy: Interim Safety Analysis of the CALGB Study 10101.

Thomas S. Lin, MD, PhD, Kathleen A. Donohue, MA, Margaret S. Lucas, BS, PA, John C. Byrd, MD, Elizabeth M. Bengtson, MD, Bercedis L. Peterson, PhD, Richard A. Larson, MD

Blood (2007) 110 (11): 755.

https://doi.org/10.1182/blood.V110.11.755.755

Published: 2007

Journal Articles

Alemtuzumab Increases Serious Infections in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) Receiving Fludarabine-Based Therapy: A Comparative Analysis of 3 Cancer and Leukemia Group B Studies (CALGB 9011, 9712, 19901).

Vicki A. Morrison, MD, Bercedis L. Peterson, PhD, Kanti R. Rai, MD, John C. Byrd, MD, Richard A. Larson, MD

Blood (2007) 110 (11): 756.

https://doi.org/10.1182/blood.V110.11.756.756

Published: 2007

Journal Articles

Multivariate Analysis of Patient and Graft Specific Factors among 330 Recipients of Unrelated Cord Blood Transplant (UCBT) To Predict Risk of Death from Opportunistic Infections in the First 6 Months after UCBT.

Paul Szabolcs, MD, Bercedis L. Peterson, PhD, Donna Niedzwiecki, PhD, Nelson Chao, MD, Joanne Kurtzberg, MD

Blood (2006) 108 (11): 2860.

https://doi.org/10.1182/blood.V108.11.2860.2860

Published: 2006

Journal Articles

Bortezomib and Pegylated Liposomal Doxorubicin as Induction Therapy for Adult Patients with Symptomatic Multiple Myeloma: Cancer and Leukemia Group B Study 10301.

Robert Z. Orlowski, MD, PhD, Bercedis L. Peterson, PhD, Ben Sanford, Asher A. Chanan-Khan, MD, Lee M. Zehngebot, MD, Peter R. Watson, MD, Michael A. Caligiuri, MD, Richard A. Larson, MD, the Cancer Leukemia Group B

Blood (2006) 108 (11): 797.

https://doi.org/10.1182/blood.V108.11.797.797

Published: 2006

Journal Articles

Response Rates in Patients with Acute Myeloid Leukemia (AML), Treated with Azacitidine, Using WHO and International Working Group (IWG) Criteria for Myelodysplastic Syndrome (MDS).

Lewis R. Silverman, MD, David R. McKenzie, MS, Bercedis L. Peterson, PhD, Richard M. Stone, MD, Bayard L. Powell, MD, Christy Mayo, MS, Jay T. Backstrom, MD, MPH, Richard A. Larson, MD, The Cancer Leukemia Group B (CALGB)

Blood (2005) 106 (11): 1848.

https://doi.org/10.1182/blood.V106.11.1848.1848

Published: 2005

Journal Articles

Analysis of Survival, AML Transformation, and Transfusion Independence in Patients with High-Risk Myelodysplastic Syndromes (MDS) Receiving Azacitidine Determined Using a Prognostic Model.

Lewis R. Silverman, MD, David R. McKenzie, MS, Bercedis L. Peterson, PhD, Erin P. Demakos, RN, CCRC, James F. Holland, MD, Richard R. Larson, MD, The Cancer Leukemia Group B (CALGB).

Blood (2005) 106 (11): 2523.

https://doi.org/10.1182/blood.V106.11.2523.2523

Published: 2005

Journal Articles

Azacitidine Prolongs Survival and Time to AML Transformation in High-Risk Myelodysplastic Syndrome (MDS) Patients ≥ 65 Years of Age.

Lewis R. Silverman, MD, David R. McKenzie, MS, Bercedis L. Peterson, PhD, Erin P. Demakos, RN, CCRC, Neil T. Malone, MA, James F. Holland, MD, Richard A. Larson, MD, The Cancer Leukemia Group B (CALGB).

Blood (2005) 106 (11): 2524.

https://doi.org/10.1182/blood.V106.11.2524.2524

Published: 2005

Journal Articles

Rates of Infection and Bleeding Are Not Increased in Patients with Myelodysplastic Syndromes (MDS) Treated with Azacitidine Compared with Supportive Care.

Lewis R. Silverman, MD, David R. McKenzie, MS, Bercedis L. Peterson, PhD, Rosalie Odchimar-Reissig, RN, MSN, CCRC, Randy Hinkle, RPh, Jay T. Backstrom, MD, Richard A. Larson, MD, The Cancer Leukemia Group B (CALGB).

Blood (2005) 106 (11): 2525.

https://doi.org/10.1182/blood.V106.11.2525.2525

Published: 2005

Journal Articles

Response Rates Using International Working Group (IWG) Criteria in Patients with Myelodysplastic Syndromes (MDS) Treated with Azacitidine.

Lewis R. Silverman, MD, David R. McKenzie, MS, Bercedis L. Peterson, PhD, Carlos M. De Castro, MD, John Ellerton, MD, Kathryn N. Knapp, MS, C.L. Beach, PharmD, Richard A. Larson, MD, The Cancer Leukemia Group B (CALGB).

Blood (2005) 106 (11): 2526.

https://doi.org/10.1182/blood.V106.11.2526.2526

Published: 2005

Journal Articles

A New Validated Myelodysplastic Syndrome (MDS) Prognostic Model for Use When Cytogenetics Are Unavailable.

Lewis R. Silverman, MD, Ulrich Germing, MD, PhD, David R. McKenzie, MS, Bercedis L. Peterson, PhD, Richard A. Larson, MD, The Cancer Leukemia Group B (CALGB).

Blood (2005) 106 (11): 2527.

https://doi.org/10.1182/blood.V106.11.2527.2527

Published: 2005

Journal Articles

Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011

John C. Byrd, Kanti Rai, Bercedis L. Peterson, Frederick R. Appelbaum, Vicki A. Morrison, Jonathan E. Kolitz, Lois Shepherd, John D. Hines, Charles A. Schiffer, Richard A. Larson

Blood (2005) 105 (1): 49–53.

https://doi.org/10.1182/blood-2004-03-0796

Published: 2005

NARROW

Decitabine Synergizes with Replication Checkpoint Inhibitors in TP53 -Mutated Acute Myeloid Leukemia

Topoisomerase I-DNA Covalent Complexes in Myeloid Malignancies: A Potential Biomarker for Topoisomerase I Inhibitor Sensitivity

4EBP1/c-MYC/PUMA and NF-κB/EGR1/BIM pathways underlie cytotoxicity of mTOR dual inhibitors in malignant lymphoid cells

mTOR Dual Inhibitor Induced Cytotoxicity Depends on 4EBP1/c-Myc/Puma and NFkB/Egr-1/Bim Pathways in Human Lymphoid Malignancies

Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies

Cytotoxicity of farnesyltransferase inhibitors in lymphoid cells mediated by MAPK pathway inhibition and Bim up-regulation

OSI-027, a Dual TORC1/TORC2 Inhibitor, Induces Bim- and Puma-Mediated Apoptosis In Lymphoid Malignancy

A Phase II Study of the Farnesyltransferase Inhibitor Tipifarnib Demonstrates Anti-Tumor Activity In Patients with Relapsed and Refractory Lymphomas

Long-Term Survival Analysis of the North American Intergroup Study C9011 Comparing Fludarabine (F) and Chlorambucil (C) in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL).

Consolidation Therapy with Subcutaneous (SC) Alemtuzumab Results in Severe Infectious Toxicity in Previously Untreated CLL Patients Who Achieve a Complete Response (CR) after Fludarabine and Rituximab (FR) Induction Therapy: Interim Safety Analysis of the CALGB Study 10101.

Alemtuzumab Increases Serious Infections in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) Receiving Fludarabine-Based Therapy: A Comparative Analysis of 3 Cancer and Leukemia Group B Studies (CALGB 9011, 9712, 19901).

Multivariate Analysis of Patient and Graft Specific Factors among 330 Recipients of Unrelated Cord Blood Transplant (UCBT) To Predict Risk of Death from Opportunistic Infections in the First 6 Months after UCBT.

Bortezomib and Pegylated Liposomal Doxorubicin as Induction Therapy for Adult Patients with Symptomatic Multiple Myeloma: Cancer and Leukemia Group B Study 10301.

Response Rates in Patients with Acute Myeloid Leukemia (AML), Treated with Azacitidine, Using WHO and International Working Group (IWG) Criteria for Myelodysplastic Syndrome (MDS).

Analysis of Survival, AML Transformation, and Transfusion Independence in Patients with High-Risk Myelodysplastic Syndromes (MDS) Receiving Azacitidine Determined Using a Prognostic Model.

Azacitidine Prolongs Survival and Time to AML Transformation in High-Risk Myelodysplastic Syndrome (MDS) Patients ≥ 65 Years of Age.

Rates of Infection and Bleeding Are Not Increased in Patients with Myelodysplastic Syndromes (MDS) Treated with Azacitidine Compared with Supportive Care.

Response Rates Using International Working Group (IWG) Criteria in Patients with Myelodysplastic Syndromes (MDS) Treated with Azacitidine.

A New Validated Myelodysplastic Syndrome (MDS) Prognostic Model for Use When Cytogenetics Are Unavailable.

Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only